Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

AbbVie

Shares of Genmab popped Wednesday after the biotech inked a deal with pharma giant AbbVie to develop cancer treatments. The deal is potentially worth billions in milestone payments.

Genmab Hits Pay Dirt On A Potential $3 Billion Deal With AbbVie

Shares of Genmab A/S GMAB, +1.33% rose 4.5% in premarket trading Wednesday, after the Denmark-based biotechnology company announced a collaboration agreement with AbbVie Inc.

Genmab's stock surges after drug development deal with AbbView valued at up to nearly $4 billion

iShares Nasdaq Biotechnology ETF

Innoviva

Novavax

Trillium Therapeutics

Vanda Pharmaceuticals

Vertex Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Top Biotech Stocks for Q3 2020

Genmab A/S (GNMSF) CEO Jan van de Winkel on Q1 2020 Results - Earnings Call Transcript

Genmab: An Attractive Biotechnology Platform Pick In March 2020

e.l.f. Beauty

Galapagos

PaySign Inc

PennyMac Financial Services

Sandstorm Gold

STORE Capital

The market is hot, but that’s no reason to forgo quality when picking the top stocks to buy now. Here are seven that stand out from the rest.

7 Top-Rated Stocks to Buy for a More Powerful Portfolio

News for Genmab - ADR Stock (GMAB)